Document:

EX-10.3

 Exhibit 10.3 
 Portions of this document have been redacted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act
of 1934, as amended. Redacted portions are indicated with the notation “[**]”. 
  
 

 
 PROVIDING COMPONENTS FOR PEOPLE TO LIVE A LONGER, HEALTHIER AND MORE FUN LIFE 

Exclusivity Agreement — Raw Materials 
 THIS AGREEMENT (this “Agreement”) is made on August 27th, 2012 (the “Effective Date”) between LULULEMON ATHLETICA CANADA INC. (“lululemon
athletica”), a company incorporated under the laws of the Province of British Columbia, having an address at 400 – 1818 Cornwall Ave, Vancouver, British Columbia and [**] (“[**]”), a company incorporated under
the laws of [**], having an address at [**]. 
 WHEREAS, the parties agree that [**] shall manufacture and supply certain fabrics materials and
products for lululemon athletica on an exclusive basis on the terms set out herein; 
 AND WHEREAS, the parties wish to protect their respective
designs, materials and other intellectual property; 
 NOW THEREFORE in consideration of ten dollars and other good and valuable consideration
(the receipt and sufficiency of which are hereby acknowledged by each of the parties hereto), the parties agree as follows: 
  

	1.	Definitions 

 In this Agreement,

  

	 	(a)	“Affiliate” means, with respect to any person, any other person that controls or is controlled by or is under common control with such person.

  

	 	(b)	“Competing Business” means any business engaged in the design, manufacture or distribution of athletic apparel or accessories, similar to or
competitive with the products of lululemon athletica or any of its Affiliates. For illustration only, as of the date of this Agreement, Competing Businesses include, but are not limited to: [**], [**], [**], [**] and [**]. 

 

	 	(c)	“Confidential Information” shall include information which [**] obtains about lululemon athletica, whether in oral, tangible or documented form, that
is of value to lululemon athletica and is not generally known in the industry or to a Competing Business of lululemon athletica. Confidential Information of lululemon athletica shall include: all technical know-how and information relating to its
business, employees, techniques, technology, technical data, technical assistance, financial affairs, information systems, marketing plans, sales strategies, research and development activities, art work, designs, plans, sketches, products, models
and prototypes of products, the configuration and assembly of components, measurements, material (whether developed or acquired by lululemon athletica or its affiliates), trade secrets, manufacturing, manufacturing information (whether or not
patentable or patented), patent applications, practical experience, methodology, specifications, photographs and other compilations of the aforesaid whether in software, written, visual or oral form regardless of whether the information is marked
as, or otherwise indicated to be, confidential at the time of disclosure and includes the Exclusive Materials and the terms of this Agreement. 

  

	 	(d)	“Exclusive Materials” means any material or fabric developed by [**] for or with lululemon athletica or its Affiliates, including, but not limited to
those listed in Schedule A to this Agreement; 

  

	 	(e)	“Supplier Agreement” means the supplier agreement between the parties dated April 20, 2011 and any amendments thereto or any successor agreement
entered into between the parties for the manufacturing and supply of fabric for lululemon athletica. 

	2.	Term 

 This
Agreement shall commence on the Effective Date and shall remain in effect for a period of five (5) years, unless either party breaches the Agreement and the non-breaching party provides prompt written notice of such breach of the Agreement, or
until the Supplier Agreement has been terminated in accordance with its terms. The parties expressly acknowledges that a breach of this Agreement shall be considered a material breach of the Supplier Agreement. Notwithstanding the foregoing the
parties agree to review and update Schedule A once every 6 months. 
  

	3.	Exclusivity 

 [**]
shall: 
  

	 	(a)	manufacture and supply the Exclusive Materials and any item manufactured using the Exclusive Materials exclusively for lululemon athletica and its Affiliates.

  

	 	(b)	not solicit, or endeavour to solicit, the sale, license or other disposition of any Exclusive Materials to any person other than lululemon athletica and its Affiliates,
whether as a raw material or as part of a manufactured item. 

  

	 	(c)	not disclose the Exclusive Materials or any Confidential Information, including any intellectual property rights related thereto, or furnish any information with
respect to the Exclusive Materials or the Confidential Information, to any person other than lululemon athletica and its Affiliates. 

  

	 	(d)	not manufacture, replicate, supply, copy, modify or otherwise reproduce the Exclusive Materials or Confidential Information for any person other than lululemon
athletica and its Affiliates. 

  

	4.	Ownership 

  

	 	(a)	[**] acknowledges and agrees that lululemon athletica owns all right, title and interest in and to the Exclusive Materials, and all intellectual property rights related
thereto, and as between lululemon athletica and [**], lululemon athletica shall have the sole right to take any and all steps necessary to obtain the entire right, title and interest in, to and under the Exclusive Materials, and the intellectual
property rights related thereto, including any patents and patent applications worldwide, except that [**] is granted a limited license to use the Exclusive Materials, and all intellectual property rights related thereto, to the extent required for
[**] to perform its obligations under this Agreement and any other agreement entered into between [**] and lululemon athletica and its Affiliates with respect to the Exclusive Materials. 

 

	 	(b)	Lululemon athletica acknowledges and agrees that [**] owns all right, title and interest in and to any materials which [**] develops independently from lululemon
athletica and which is not based in whole or in part on the Exclusive Materials or work done with lululemon athletica in the development of the Exclusive Materials (the “[**] Materials”). [**] shall offer lululemon the first right to use
the [**] Materials on an exclusive basis, in advance of offering the [**] Materials to any other customer. Lululemon athletica shall not knowingly disclose to any third party fabric suppliers or permit the duplication of [**] Materials by its other
suppliers without the prior written consent of [**]. 

  

	 	(c)	Notwithstanding the foregoing, in the event that lululemon athletica chooses not to commercialize an item of the Exclusive Materials within 18 months from the date that
such Exclusive Material was fully developed, lululemon athletica shall provide [**] with written notice, identifying which items it does not intend to commercialize, and, upon the written request of [**], lululemon athletica shall transfer all
right, title and interest in and to the identified item and the intellectual property rights related thereto to [**] and shall no longer be considered Exclusive Materials. 

 

	 	(d)	For the [**] Materials in which lululemon athletica selects for bulk order production, [**] shall continue to hold all right, title and interest in and to any such [**]
Materials, including all intellectual property rights related thereto. 

  

- 2 - 

	5.	Confidentiality 

  

	 	(a)	The parties acknowledge and agree that all confidential information shared with each party has been and shall be received by the other party in the strictest confidence
and shall be held and used by the parties only in accordance with and subject to the terms of this Agreement. During the term of this Agreement and at all times thereafter, neither party shall disclose, and shall maintain the confidentiality of, all
confidential information. The parties shall use at least the same degree of care as it uses to protect its own confidential information, but no less than a reasonable degree of care, to maintain in confidence the confidential information. Each party
shall ensure that each of its employees, consultants, agents and representatives who have had or shall have access to the confidential information comply with this Agreement. The parties shall not disclose or make available any confidential
information to any subcontractor retained by the other party without first obtaining (i) written consent from the party whose confidential information is sought to be disclosed and (ii) written agreement from the subcontractor to abide by
these confidentiality obligations. All confidential information shall be owned by and remain the sole and exclusive property of the disclosing party . The foregoing obligations shall not apply to any item of confidential information that (i) is
at the time of disclosure, or thereafter becomes, part of the public domain by any means other either party’s breach of its obligations hereunder, (ii) was known to the other party at the time of disclosure as evidenced by written records
or (iii) is, at any time, disclosed to the other party by any third party having the right to disclose the same. To the extent that either party is required by law to disclose any confidential information it shall be permitted to do so for the
limited purpose so required provided that notice is first delivered to lululemon athletica in a timely manner so that it has the opportunity to contest the potential disclosure. 

 

	 	(b)	To secure the confidentiality attaching to the confidential information, each party shall: 

 

	 	i.	keep separate all confidential information and all information generated by either party based thereon from all documents and other records of the disclosing party;

  

	 	ii.	keep all documents and any other material bearing or incorporating any of the confidential information at the place of business of either party listed above or such
other place as is agreed in writing between the parties; 

  

	 	iii.	restrict access to the confidential information exclusively to those individuals who have a need to know the information and who are parties to this Agreement and then
only where they have a reasonable need to see and use it solely for the purpose fulfilling the parties’ obligations under the Supplier Agreement. 

  

	 	iv.	make no copies of any of the confidential information without the prior written consent of the other party; and 

 

	 	v.	upon receiving written notice from either party, deliver up to the requesting party all documents, samples and all other material in the possession, custody or control
of the other party that bear or incorporate any part of the confidential information including all copies made by either party and, in the case of material in software form, delete the same from all parties’computer or electronic information
retrieval systems. 

  

	 	(c)	Upon termination of this Agreement or upon receiving reasonable prior written request from either party, but in no event no less than ten (10) business days after
receiving such written notice, the other party shall promptly return to the requesting party all Confidential Information in the other party’s possession, custody or control and cease any further use of the confidential information.

  

	 	(d)	Each party acknowledges and agrees that the other party may be irreparably harmed and may have no adequate remedy at law for breach of the confidentiality provisions
set out in this Agreement and that the other party shall be entitled to seek injunctive or other affirmative relief in addition to any of the rights or remedies otherwise available at law 

  

- 3 - 

	6.	Indemnity 

 Each party shall
indemnify, hold harmless and defend the other party, its Affiliates, servants, agents, employees, invitees and representatives from and against any and all losses, damages, expenses, claims, suits and demands (including legal fees and expenses on a
solicitor and client basis) resulting from damages or injuries caused by or arising out any breach of the representations, warranties or covenants contained in this Exclusivity Agreement. 

 

	7.	Acknowledgement 

 Each party
acknowledges that the rights granted to in this Agreement are fair and reasonable and that each party has received adequate consideration for the grant of such rights pursuant to this Agreement and the Supplier Agreement. 

 

	8.	Entire Agreement 

 This Agreement
represents the entire agreement between the parties with respect to the subject matter hereof and supersedes any and all written, electronic, oral or other communications between the parties with respect to such subject matter. Notwithstanding the
foregoing, the rights and obligations set out in this Agreement are in addition to, and not a replacement of, those set out in the Supplier Agreement. 
  

	9.	Severability 

 If any provision in
this Agreement shall be held to be illegal, invalid or unenforceable, in whole or in part, under any law, such provision or part shall to the extent of the illegality, invalidity or unenforceability be deemed not be form part of this Agreement and
shall not affect the legality, validity and enforceability of the remainder of this Agreement. 
  

	10.	Successors 

 This Agreement shall
enure to the benefit of and be binding upon the parties hereto and their respective administrators, successors and permitted assigns. 
  

	11.	Governing Law, Jurisdiction and Venue  

 Regardless of any conflict of law or choice of law principles that might otherwise apply, lululemon athletica and Supplier agree that this Agreement shall be governed by and construed in all respects in
accordance with the laws of the Province of British Columbia. Each of the parties also expressly agrees and acknowledges that the Province of British Columbia has a reasonable relationship to each of the parties and/or this Agreement. As to any
dispute, claim, or litigation arising out of or relating in any way to this Agreement or the transaction at issue in this Agreement, each of the parties agrees and consents to the non-exclusive jurisdiction of the courts of the Province of British
Columbia located in Vancouver, British Columbia, Canada and irrevocably waives, to the fullest extent permitted by law (i) any objection that it may now or hereafter have to laying venue and any suit, action or proceeding brought in such court,
(ii) any claim that any suit action or proceeding brought in such court has been brought in an inconvenient forum and (iii) any defence that it may now or hereafter have based on lack of personal jurisdiction in such forum. 

 

	12.	Arbitration 

 In the event of any
controversy or claim arising out of or relating to this agreement, including its validity or a breach thereof, the parties hereto shall consult and negotiate with each other and shall attempt to reach a satisfactory solution. If the parties do
not resolve their dispute within a period of 30 days after written notice of the dispute by either party to the other, any unresolved controversy or claim shall be settled by arbitration administered by the International Centre for Dispute
Resolution in accordance with its International Arbitration Rules. The number of arbitrators shall one. The place of arbitration shall be Vancouver, British Columbia, and 

  

- 4 - 

 
the language of the arbitration shall be English. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, its costs and expenses, including attorneys’
fees. Judgment upon any award rendered by the arbitrator may be entered in any court of competent jurisdiction. No information concerning an arbitration, beyond the names of the parties and the relief requested, may be unilaterally disclosed to a
third party by any party unless required by law. Any documentary or other evidence given by a party or witness in the arbitration shall be maintained as confidential by any party whose access to such evidence arises exclusively as a result of its
participation in the arbitration, and shall not be disclosed to any third party (other than a witness or expert), except as may be required by law. 
  

	13.	Waiver Of Trial By Jury 

 Each of
the parties hereby agrees that it waives all right to trial by jury in any proceeding arising out of or relating to this Agreement and the transactions contemplated hereby. 

 

	14.	Counterparts 

 This Agreement may
be executed in any number of counterparts, each of which shall be deemed to be an original and all of which taken together shall be deemed to constitute one and the same instrument. 

 

	15.	Electronic Execution 

 Delivery of
an executed signature page to this Agreement by any party by electronic transmission shall be as effective as delivery of a manually executed copy of this Agreement by such party. 
 IN WITNESS WHEREOF the parties hereto have caused this Agreement to be executed as of the date first above written. 
  

									
	LULULEMON ATHLETICA CANADA INC.	 		 	[**]
					
	By:	 	  
	 		 	By:	 	  

		 	Authorized Signatory	 		 		 	Authorized Signatory
					
	Name: 	 	  
	 		 	Name: 	 	  

					
	Title: 	 	  
	 		 	Title: 	 	  

					
	Date: 	 	  
	 		 	Date: 	 	  

  

- 5 -EX-4.2

 Exhibit 4.2 
 Execution Copy 
 AGIOS PHARMACEUTICALS, INC. 

SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 November 16, 2011 

 TABLE OF CONTENTS 

 

									
	 	  	 	  	 	  	Page	 
		
	Recitals	  	 	1	  
			
	1.	  	Certain Definitions	  	 	1	  
			
	2.	  	Registration Rights	  	 	5	  
				
		  	2.1	  	Required Registrations	  	 	5	  
				
		  	2.2	  	Incidental Registration	  	 	6	  
				
		  	2.3	  	Registration Procedures	  	 	7	  
				
		  	2.4	  	Allocation of Expenses	  	 	9	  
				
		  	2.5	  	Indemnification and Contribution	  	 	9	  
				
		  	2.6	  	Other Matters with Respect to Underwritten Offerings	  	 	11	  
				
		  	2.7	  	Information by Holder	  	 	11	  
				
		  	2.8	  	“Lock-Up” Agreement; Confidentiality of Notices	  	 	11	  
				
		  	2.9	  	Limitations on Subsequent Registration Rights	  	 	12	  
				
		  	2.10	  	Rule 144 Requirements	  	 	12	  
				
		  	2.11	  	Termination	  	 	13	  
			
	3.	  	Right of First Refusal	  	 	13	  
				
		  	3.1	  	Rights of Purchasers to Acquire Offered Securities	  	 	13	  
				
		  	3.2	  	Termination	  	 	15	  
			
	4.	  	Covenants	  	 	15	  
				
		  	4.1	  	Negative Covenants	  	 	15	  
				
		  	4.2	  	Observation	  	 	16	  
				
		  	4.3	  	Financial Statements and Budget	  	 	17	  
				
		  	4.4	  	Agreements with Employees; Options	  	 	17	  
				
		  	4.5	  	Board of Directors	  	 	18	  
				
		  	4.6	  	Termination of Covenants	  	 	18	  
			
	5.	  	Confidentiality; Acknowledgement of Investor Activity	  	 	19	  
			
	6.	  	Transfers of Rights; Calculation of Share Numbers	  	 	19	  
				
		  	6.1	  	Transfer of Rights	  	 	19	  
				
		  	6.2	  	Calculation of Share Numbers	  	 	19	  
			
	7.	  	General	  	 	20	  
				
		  	7.1	  	Massachusetts Business Trust	  	 	20	  
				
		  	7.2	  	Severability	  	 	20	  
				
		  	7.3	  	Specific Performance	  	 	20	  

  
 - i -

									
				
		  	7.4	  	Governing Law	  	 	20	  
				
		  	7.5	  	Notices	  	 	20	  
				
		  	7.6	  	Amendment and Restatement of Prior Agreement; Complete Agreement	  	 	21	  
				
		  	7.7	  	Amendments and Waivers	  	 	21	  
				
		  	7.8	  	Pronouns	  	 	21	  
				
		  	7.9	  	Counterparts; Facsimile Signatures	  	 	21	  
				
		  	7.10	  	Section Headings and References	  	 	22	  
		
	Exhibit A – List of Purchasers	  			

  
 - ii -

 AGIOS PHARMACEUTICALS, INC. 

SECOND AMENDED AND RESTATED 
 INVESTOR RIGHTS AGREEMENT 
 This Agreement dated as of November 16,
2011 is entered into by and among Agios Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Lewis Cantley, Tak Mak, Craig Thompson and Michael Su (individually, a “Founder” and collectively, the
“Founders”), and the individuals and entities listed on Exhibit A attached hereto (the “Purchasers”). 
 Recitals 
 WHEREAS, the Company and certain Purchasers (the
“Existing Purchasers”) have previously entered into that certain Amended and Restated Investor Rights Agreement, dated as of April 14, 2010 (the “Prior Agreement”), which provides for certain arrangements with
respect to (i) the registration of shares of capital stock of the Company under the Securities Act (as defined below), (ii) certain Purchasers’ right of first refusal with respect to certain issuances of securities of the Company, and
(iii) certain covenants of the Company; 
 WHEREAS, the Company and certain Purchasers have entered into a Series C-1
Convertible Preferred Stock and Series C-2 Convertible Preferred Stock Purchase Agreement of even date herewith (the “Purchase Agreement”); and 
 WHEREAS, the Company and the Existing Purchasers desire to amend and restate the Prior Agreement, to add new Purchasers as parties to this Agreement and to accept the rights created pursuant hereto in
lieu of the rights created under the Prior Agreement. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants
contained in this Agreement, the parties hereto agree as follows: 
 1. Certain Definitions. 

As used in this Agreement, the following terms shall have the following respective meanings: 

“Affiliated Party” means, with respect to any Purchaser, any person or entity which, directly or indirectly, controls,
is controlled by or is under common control with such Purchaser, including, without limitation, any general partner, officer or director of such Purchaser and any venture capital fund now or hereafter existing which is controlled by one or more
general partners of, or shares the same management company as, such Purchaser. 
 “Available Undersubscription
Amount” means the difference between the total of all of the Basic Amounts available for purchase by Qualified Purchasers pursuant to Section 3.1 and the Basic Amounts subscribed for pursuant to Section 3.1. 

“Basic Amount” means, with respect to a Qualified Purchaser, its pro rata portion of the Offered Securities determined
by multiplying the number of Offered Securities by a fraction, the numerator of which is the aggregate number of shares of Common Stock issuable upon conversion of all Shares then held by such Qualified Purchaser and the denominator of which is the
total number of shares of Common Stock then outstanding (giving effect to the conversion into Common Stock of all outstanding shares of convertible preferred stock but excluding all shares of Common Stock (including shares issued upon exercise of
options) issued to employees of the Company after the date hereof). 

 “Code” means the Internal Revenue Code of 1986, as amended. 

“Commission” means the Securities and Exchange Commission, or any other federal agency at the time administering the
Securities Act. 
 “Common Stock” means the common stock, $0.001 par value per share, of the Company.

 “Company” has the meaning ascribed to it in the introductory paragraph hereto. 

“Company Sale” means: (a) a merger or consolidation in which (i) the Company is a constituent party, or
(ii) a Company Subsidiary is a constituent party and the Company issues shares of its capital stock pursuant to such merger or consolidation, except in the case of either clause (i) or (ii) any such merger or consolidation involving
the Company or a Company Subsidiary in which the shares of capital stock of the Company outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock which
represent, immediately following such merger or consolidation, more than 50% by voting power of the capital stock of (A) the surviving or resulting corporation or (B) if the surviving or resulting corporation is a wholly owned subsidiary
of another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation; (b) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or
series of related transactions, by the Company or a Company Subsidiary of all or substantially all the assets of the Company and the Company Subsidiaries taken as a whole (except where such sale, lease, transfer, exclusive license or other
disposition is to a wholly owned Company Subsidiary); or (c) the sale or transfer, in a single transaction or series of related transactions, by the stockholders of the Company of more than 50% by voting power of the then-outstanding capital
stock of the Company to any person or entity or group of affiliated persons or entities in which (i) the Company is party to such transaction or transactions or (ii) the acquiring persons or entities are not Affiliated Parties of holders
of Series A Convertible Preferred Stock of the Company. 
 “Company Subsidiary” means any corporation,
partnership, trust, limited liability company or other non-corporate business enterprise in which the Company (or another Company Subsidiary) holds stock or other ownership interests representing (a) more than 50% of the voting power of all
outstanding stock or ownership interests of such entity or (b) the right to receive more than 50% of the net assets of such entity available for distribution to the holders of outstanding stock or ownership interests upon a liquidation or
dissolution of such entity. 
 “Confidential Information” means any information that is labeled as
confidential, proprietary or secret which a Purchaser obtains from the Company pursuant to financial statements, reports and other materials provided by the Company to such Purchaser pursuant to this Agreement or pursuant to visitation or inspection
rights granted hereunder. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended, or any
successor federal statute, and the rules and regulations of the Commission issued under such Act, as they each may, from time to time, be in effect. 
 “Fidelity Purchasers” means each of Fidelity Select Portfolios: Pharmaceuticals Portfolio, Fidelity Select Portfolios: Biotechnology Portfolio, Fidelity Advisor Series VII: Fidelity
Advisor Biotechnology Fund, Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund, Fidelity Contrafund: Fidelity Advisor New Insights Fund, Fidelity Securities Fund: Fidelity Small Cap Opportunities Fund and Fidelity Capital Trust: Fidelity
Small Cap Independence Fund. 
 “Indemnified Party” means a party entitled to indemnification pursuant to
Section 2.5. 

  
 - 2 -

 “Indemnifying Party” means a party obligated to provide indemnification
pursuant to Section 2.5. 
 “Independent Directors” has the meaning given to such term in the Second
Amended and Restated Stockholders’ Voting Agreement by and among the Company, the Purchasers and the Founders, dated on or about the date hereof. 
 “Initial Public Offering” means the initial underwritten public offering of shares of Common Stock pursuant to an effective Registration Statement. 

“Initiating Holders” means the Purchasers initiating a request for registration pursuant to Section 2.1(a) or
2.1(b), as the case may be. 
 “Notice of Acceptance” means a written notice from a Purchaser to the Company
containing the information specified in Section 3.1(b). 
 “Offer” means a written notice of any proposed
or intended issuance, sale or exchange of Offered Securities containing the information specified in Section 3.1(a). 

“Offered Securities” means (a) any shares of Common Stock, (b) any other equity securities of the Company,
including, without limitation, shares of preferred stock, (c) any option, warrant or other right to subscribe for, purchase or otherwise acquire any equity securities of the Company, or (d) any debt securities convertible into capital
stock of the Company. 
 “Other Holders” means holders of securities of the Company (other than Purchasers) who
are entitled, by contract with the Company, to have securities included in a Registration Statement. 

“Prospectus” means the prospectus included in any Registration Statement, as amended or supplemented by an amendment or
prospectus supplement, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus. 
 “Purchase Agreement” has the meaning ascribed to it in the recitals hereto. 
 “Purchaser” has the meaning ascribed to it in the introductory paragraph hereto. 
 “Qualified Public Offering” means the closing of the sale of shares of Common Stock to the public in a firm-commitment underwritten public offering pursuant to an effective registration
statement under the Securities Act resulting in at least $30,000,000 of gross proceeds to the Corporation and with either (a) a price of at least $5.00 per share (subject to appropriate adjustment in the event of any stock dividend, stock
split, combination or other similar recapitalization with respect to the Common Stock) or (b) a listing of the Common Stock on a nationally recognized securities exchange or trading system. 

“Qualified Purchaser” means a Purchaser that is an “accredited investor” within the meaning of Rule 501(a)
under the Securities Act. 
 “Refused Securities” means those Offered Securities as to which a Notice of
Acceptance has not been given by the Qualified Purchasers pursuant to Section 3.1. 
 “Registrable Shares”
means (a) the shares of Common Stock issued or issuable upon conversion of the Shares, (b) any IPO Shares (as defined in the Series B Purchase Agreement) purchased 

  
 - 3 -

 
in a Private Placement (as defined in the Series B Purchase Agreement), and (c) any other shares of Common Stock issued in respect of such shares (because of stock splits, stock dividends,
reclassifications, recapitalizations or similar events); provided, however, that shares of Common Stock which are Registrable Shares shall cease to be Registrable Shares (i) upon any sale pursuant to a Registration Statement or
Rule 144 under the Securities Act or (ii) upon any sale in any manner to a person or entity which is not entitled, pursuant to Section 6.1, to the rights under this Agreement or (iii) at such time, following an Initial Public
Offering, as they become eligible for sale pursuant to Rule 144(b)(1)(i) under the Securities Act; provided, however, with respect to clause (iii), a period of at least one year, as determined in accordance with paragraph (d) of
Rule 144 under the Securities Act, has elapsed since the later of the date such shares were acquired from the Company or an affiliate of the Company. Wherever reference is made in this Agreement to a request or consent of holders of a certain
percentage of Registrable Shares, the determination of such percentage shall include shares of Common Stock issuable upon conversion of the Shares even if such conversion has not been effected. 

“Registration Expenses” means all expenses incurred by the Company in complying with the provisions of Section 2,
including, without limitation, all registration and filing fees, exchange listing fees, printing expenses, fees and expenses of counsel for the Company and the fees and expenses of one counsel selected by the Selling Stockholders to represent the
Selling Stockholders, state Blue Sky fees and expenses, and the expense of any special audits incident to or required by any such registration, but excluding underwriting discounts, selling commissions and the fees and expenses of Selling
Stockholders’ own counsel (other than the counsel selected to represent all Selling Stockholders). 
 “Registration
Statement” means a registration statement filed by the Company with the Commission for a public offering and sale of securities of the Company (other than a registration statement on Form S-8 or Form S-4, or their successors, or any other
form for a similar limited purpose, or any registration statement covering only securities proposed to be issued in exchange for securities or assets of another corporation). 
 “Securities Act” means the Securities Act of 1933, as amended, or any successor federal statute, and the rules and regulations of the Commission issued under such Act, as they each may,
from time to time, be in effect. 
 “Selling Stockholder” means any Purchaser owning Registrable Shares
included in a Registration Statement. 
 “Series A Directors” means the directors designated by the holders of
Series A Convertible Preferred Stock of the Company pursuant to the Second Amended and Restated Stockholders’ Voting Agreement by and among the Company, the Purchasers and the Founders, dated on or about the date hereof. 

“Series B Purchase Agreement” means the Series B Convertible Preferred Stock Purchase Agreement, dated as of
April 14, 2010, by and between the Company and Celgene Corporation. 
 “Shares” means shares of Series A
Convertible Preferred Stock, $0.001 par value per share, of the Company, shares of Series B Convertible Preferred Stock, $0.001 par value per share, of the Company, Series C-1 Convertible Preferred Stock, $0.001 par value per share, of the Company
and Series C-2 Convertible Preferred Stock, $0.001 par value per share, of the Company. 
 “Undersubscription
Amount” means, with respect to a Qualified Purchaser, any additional portion of the Offered Securities attributable to the Basic Amounts of other Qualified Purchasers as such Qualified Purchaser indicates it will purchase or acquire should
the other Qualified Purchasers subscribe for less than their Basic Amounts. 

  
 - 4 -

 2. Registration Rights. 

2.1 Required Registrations. 
 (a) At any time after the earlier of (i) five years after the date hereof or (ii) six months after the closing of the Initial Public Offering, a Purchaser or Purchasers holding in the aggregate
a majority of the Registrable Shares then outstanding may request, in writing, that the Company effect the registration on Form S-1 (or any successor form) of Registrable Shares owned by such Purchaser or Purchasers having an aggregate value of
at least $5,000,000 (based on the market price or fair value on the date of such request). 
 (b) At any time after the Company
becomes eligible to file a Registration Statement on Form S-3 (or any successor form relating to secondary offerings), a Purchaser or Purchasers holding in the aggregate at least 25% of the Registrable Shares may request, in writing, that the
Company effect the registration on Form S-3 (or such successor form), of Registrable Shares having an aggregate value of at least $5,000,000 (based on the public market price on the date of such request). 

(c) Upon receipt of any request for registration pursuant to this Section 2, the Company shall promptly give written notice of such
proposed registration to all other Purchasers. Such Purchasers shall have the right, by giving written notice to the Company within 30 days after the Company provides its notice, to elect to have included in such registration such of their
Registrable Shares as such Purchasers may request in such notice of election, subject in the case of an underwritten offering to the terms of Section 2.1(d). Thereupon, the Company shall, as expeditiously as possible, use its best efforts to
effect the registration on an appropriate registration form of all Registrable Shares which the Company has been requested to so register; provided, however, that in the case of a registration requested under Section 2.1(b), the Company will
only be obligated to effect such registration on Form S-3 (or any successor form). 
 (d) If the Initiating Holders intend to
distribute the Registrable Shares covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1(a) or (b), as the case may be, and the Company shall include such
information in its written notice referred to in Section 2.1(c). In such event, (i) the right of any other Purchaser to include its Registrable Shares in such registration pursuant to Section 2.1(a) or (b), as the case may be, shall
be conditioned upon such other Purchaser’s participation in such underwriting on the terms set forth herein, and (ii) all Purchasers including Registrable Shares in such registration shall enter into an underwriting agreement upon
customary terms with the underwriter or underwriters managing the offering; provided that such underwriting agreement shall not provide for indemnification or contribution obligations on the part of the Purchasers materially greater than the
obligations of the Purchasers pursuant to Section 2.5. The Initiating Holders shall have the right to select the managing underwriter(s) for any underwritten offering requested pursuant to Section 2.1(a) or (b), subject to the approval of
the Company, which approval will not be unreasonably withheld, conditioned or delayed. If any Purchaser who has requested inclusion of its Registrable Shares in such registration as provided above disapproves of the terms of the underwriting, such
Purchaser may elect, by written notice to the Company, to withdraw its Registrable Shares from such Registration Statement and underwriting. If the Company desires that any officers or directors of the Company holding securities of the Company be
included in any registration for an underwritten offering requested pursuant to Section 2.1 or if Other Holders request such inclusion, the Company may include the securities of such officers, directors and Other Holders in such registration
and underwriting on the terms set forth herein applicable to the Purchasers. If the managing underwriter 

  
 - 5 -

 
advises the Company in writing that marketing factors require a limitation on the number of shares to be underwritten, the shares held by officers or directors of the Company and by Other Holders
(other than Registrable Shares) shall be excluded from such Registration Statement and underwriting to the extent deemed advisable by the managing underwriter, and if a further reduction of the number of shares is required, the number of shares that
may be included in such Registration Statement and underwriting shall be allocated among all Purchasers requesting registration in proportion, as nearly as practicable, to the respective number of Registrable Shares held by them on the date of the
request for registration made by the Initiating Holders pursuant to Section 2.1(a) or (b), as the case may be. If any such stockholder would thus be entitled to include more shares than such stockholder requested to be registered, the excess
shall be allocated among other participating stockholders pro rata in the manner described in the preceding sentence. If the managing underwriter has not limited the number of Registrable Shares or other securities to be underwritten, the Company
may include securities for its own account in such registration if the managing underwriter so agrees and if the number of Registrable Shares and other securities which would otherwise have been included in such registration and underwriting will
not thereby be limited. 
 (e) The Company shall not be required to effect more than (i) two registrations pursuant to
Section 2.1(a) or (ii) in any 12-month period, two registrations pursuant to Section 2.1(b). In addition, the Company shall not be required to effect any registration within six months after the effective date of the Registration
Statement relating to the Initial Public Offering. For purposes of this Section 2.1(e), a Registration Statement shall not be counted until such time as such Registration Statement has been declared effective by the Commission (unless the
Initiating Holders withdraw their request for such registration (other than as a result of information concerning the business or financial condition of the Company which is made known to the Purchasers after the date on which such registration was
requested) and elect not to pay the Registration Expenses therefor pursuant to Section 2.4). For purposes of this Section 2.1(e), a Registration Statement shall not be counted if, as a result of an exercise of the underwriter’s
cut-back provisions, less than 50% of the total number of Registrable Shares that Purchasers have requested to be included in such Registration Statement are so included. 
 (f) If at the time of any request to register Registrable Shares by Initiating Holders pursuant to this Section 2.1, the Company is engaged or has plans to engage in a registered public offering or
is engaged in any other activity which, in the good faith determination of the Company’s Board of Directors, would be adversely affected by the requested registration, then the Company may at its option direct that such request be delayed for a
period not in excess of 30 days from the date of such request, such right to delay a request to be exercised by the Company not more than twice in any 12-month period. 
 2.2 Incidental Registration. 
 (a) Whenever the Company proposes to file a
Registration Statement covering shares of Common Stock at any time and from time to time, it will, prior to such filing, give written notice to all Purchasers of its intention to do so. Upon the written request of a Purchaser or Purchasers given
within 20 days after the Company provides such notice (which request shall state the intended method of disposition of such Registrable Shares), unless (i) the Registration Statement is to be filed pursuant to Section 2.1 hereof,
(ii) the Registration Statement covers shares to be sold solely for the account of Other Holders, which shares were acquired pursuant to either (I) an acquisition of a company of which they were formerly stockholders, (II) a “private
placement” under the Securities Act or (III) Rule 144A under the Securities Act, or (iii) no Registrable Shares are to be included in the Registration Statement as a result of a written notice from the managing underwriter pursuant to
Section 2.2(b), the Company shall use its best efforts to cause all Registrable Shares which the Company has been requested by such Purchaser or Purchasers to register to be registered under the Securities Act to the extent

  
 - 6 -

 
necessary to permit their sale or other disposition in accordance with the intended methods of distribution specified in the request of such Purchaser or Purchasers; provided that the Company
shall have the right to postpone or withdraw any registration effected pursuant to this Section 2.2 without obligation to any Purchaser. 
 (b) If the registration for which the Company gives notice pursuant to Section 2.2(a) is a registered public offering involving an underwriting, the Company shall so advise the Purchasers as a part
of the written notice given pursuant to Section 2.2(a). In such event, (i) the right of any Purchaser to include its Registrable Shares in such registration pursuant to this Section 2.2 shall be conditioned upon such Purchaser’s
participation in such underwriting on the terms set forth herein and (ii) all Purchasers including Registrable Shares in such registration shall enter into an underwriting agreement upon customary terms with the underwriter or underwriters
selected for the underwriting by the Company. If any Purchaser who has requested inclusion of its Registrable Shares in such registration as provided above disapproves of the terms of the underwriting, such person may elect, by written notice to the
Company, to withdraw its shares from such Registration Statement and underwriting. If the managing underwriter advises the Company in writing that marketing factors require a limitation on the number of shares to be underwritten, the shares held by
holders of securities of the Company other than Purchasers and Other Holders shall be excluded from such Registration Statement and underwriting to the extent deemed advisable by the managing underwriter, and, if a further reduction of the number of
shares is required, the shares held by Other Holders shall be excluded from such Registration Statement and underwriting to the extent deemed advisable by the managing underwriter, and, if a further reduction of the number of shares is required, the
number of shares that may be included in such Registration Statement and underwriting shall be allocated among all Purchasers requesting registration in proportion, as nearly as practicable, to the respective number of shares of Common Stock (on an
as-converted basis) held by them on the date the Company gives the notice specified in Section 2.2(a). If any Purchaser would thus be entitled to include more shares than such holder requested to be registered, the excess shall be allocated
among other requesting Purchasers pro rata in the manner described in the preceding sentence. 
 2.3 Registration
Procedures. 
 (a) If and whenever the Company is required by the provisions of this Agreement to use its best efforts to
effect the registration of any Registrable Shares under the Securities Act, the Company shall: 
 (i) file with the Commission
a Registration Statement with respect to such Registrable Shares and use its best efforts to cause that Registration Statement to become effective as soon as possible; 
 (ii) as expeditiously as possible prepare and file with the Commission any amendments and supplements to the Registration Statement and the prospectus included in the Registration Statement as may be
necessary to comply with the provisions of the Securities Act (including the anti-fraud provisions thereof) and to keep the Registration Statement effective for 12 months from the effective date or such lesser period until all such Registrable
Shares are sold; 
 (iii) as expeditiously as possible furnish to each Selling Stockholder such reasonable numbers of copies of
the Prospectus, including any preliminary Prospectus, in conformity with the requirements of the Securities Act, and such other documents as such Selling Stockholder may reasonably request in order to facilitate the public sale or other disposition
of the Registrable Shares owned by such Selling Stockholder; 

  
 - 7 -

 (iv) as expeditiously as possible use its best efforts to register or qualify the
Registrable Shares covered by the Registration Statement under the securities or Blue Sky laws of such states as the Selling Stockholders shall reasonably request, and do any and all other acts and things that may be necessary or desirable to enable
the Selling Stockholders to consummate the public sale or other disposition in such states of the Registrable Shares owned by the Selling Stockholders; provided, however, that the Company shall not be required in connection with this paragraph
(iv) to qualify as a foreign corporation or to execute a general consent to service of process in any jurisdiction or to amend its Certificate of Incorporation or By-laws in a manner that the Board of Directors of the Company determines is
inadvisable; 
 (v) as expeditiously as possible, cause all such Registrable Shares to be listed on each securities exchange or
automated quotation system on which similar securities issued by the Company are then listed; 
 (vi) promptly provide a
transfer agent and registrar for all such Registrable Shares not later than the effective date of such Registration Statement; 

(vii) promptly make available for inspection by the Selling Stockholders, any managing underwriter participating in any disposition
pursuant to such Registration Statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the Selling Stockholders, all financial and other records, pertinent corporate documents and properties of the
Company and cause the Company’s officers, directors, employees and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant or agent in connection with such Registration
Statement; 
 (viii) notify each Selling Stockholder, promptly after it shall receive notice thereof, of the time when such
Registration Statement has become effective or a supplement to any Prospectus forming a part of such Registration Statement has been filed; and 
 (ix) as expeditiously as possible following the effectiveness of such Registration Statement, notify each seller of such Registrable Shares of any request by the Commission for the amending or
supplementing of such Registration Statement or Prospectus. 
 (b) If the Company has delivered a Prospectus to the Selling
Stockholders and after having done so the Prospectus is amended to comply with the requirements of the Securities Act, the Company shall promptly notify the Selling Stockholders and, if requested, the Selling Stockholders shall immediately cease
making offers of Registrable Shares and return all Prospectuses to the Company. The Company shall promptly provide the Selling Stockholders with revised Prospectuses and, following receipt of the revised Prospectuses, the Selling Stockholders shall
be free to resume making offers of the Registrable Shares. 
 (c) In the event that, in the judgment of the Company, it is
advisable to suspend use of a Prospectus included in a Registration Statement due to pending material developments or other events that have not yet been publicly disclosed and as to which the Company believes public disclosure would be detrimental
to the Company, the Company shall notify all Selling Stockholders to such effect, and, upon receipt of such notice, each such Selling Stockholder shall immediately discontinue any sales of Registrable Shares pursuant to such Registration Statement
until such Selling Stockholder has received copies of a supplemented or amended Prospectus or until such Selling Stockholder is advised in writing by the Company that the then current Prospectus may be used and has received copies of any additional
or supplemental filings that are incorporated or deemed incorporated by reference in such Prospectus. Notwithstanding anything to the contrary herein, the Company shall not exercise its rights under this Section 2.3(c) to suspend sales of
Registrable Shares for a period in excess of 30 days consecutively or 60 days in any 365-day period. 

  
 - 8 -

 2.4 Allocation of Expenses. The Company will pay all Registration Expenses for all
registrations under this Agreement; provided, however, that if a registration under Section 2.1 is withdrawn at the request of the Initiating Holders (other than as a result of information concerning the business or financial
condition of the Company which is made known to the Selling Stockholders after the date on which such registration was requested) and if the Initiating Holders elect not to have such registration counted as a registration requested under
Section 2.1, the Selling Stockholders shall pay the Registration Expenses of such registration pro rata in accordance with the number of their Registrable Shares included in such registration. 

2.5 Indemnification and Contribution. 
 (a) In the event of any registration of any of the Registrable Shares under the Securities Act pursuant to this Agreement, the Company will indemnify and hold harmless each Selling Stockholder, each
underwriter of such Registrable Shares, and each other person, if any, who controls such Selling Stockholder or underwriter within the meaning of the Securities Act or the Exchange Act against any losses, claims, damages or liabilities, joint or
several, to which such Selling Stockholder, underwriter or controlling person may become subject under the Securities Act, the Exchange Act, state securities or Blue Sky laws or otherwise, insofar as such losses, claims, damages or liabilities (or
actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of any material fact contained in any Registration Statement under which such Registrable Shares were registered under the
Securities Act, any preliminary prospectus or final prospectus contained in the Registration Statement, or any amendment or supplement to such Registration Statement, (ii) the omission or alleged omission to state a material fact required to be
stated therein or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under
the Securities Act, the Exchange Act or any state securities law in connection with the Registration Statement or the offering contemplated thereby; and the Company will reimburse such Selling Stockholder, underwriter and each such controlling
person for any legal or any other expenses reasonably incurred by such Selling Stockholder, underwriter or controlling person in connection with investigating or defending any such loss, claim, damage, liability or action; provided,
however, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any untrue statement or omission made in such Registration Statement, preliminary
prospectus or prospectus, or any such amendment or supplement, in reliance upon and in conformity with information furnished to the Company, in writing, by or on behalf of such Selling Stockholder, underwriter or controlling person specifically for
use in the preparation thereof. 
 (b) In the event of any registration of any of the Registrable Shares under the Securities
Act pursuant to this Agreement, each Selling Stockholder, severally and not jointly, will indemnify and hold harmless the Company, each of its directors and officers and each underwriter (if any) and each person, if any, who controls the Company or
any such underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages or liabilities, joint or several, to which the Company, such directors and officers, underwriter or controlling person may become
subject under the Securities Act, Exchange Act, state securities or Blue Sky laws or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or
alleged untrue statement of a material fact contained in any Registration Statement under which such Registrable Shares were registered under the Securities Act, any preliminary prospectus or final prospectus contained in the Registration Statement,
or any amendment or supplement to the Registration Statement, or (ii) any omission or alleged omission to state a material fact required to be 

  
 - 9 -

 
stated therein or necessary to make the statements therein not misleading, if and to the extent (and only to the extent), in the case of both clauses (i) and (ii), that the statement or
omission was made in reliance upon and in conformity with information relating to such Selling Stockholder furnished in writing to the Company by or on behalf of such Selling Stockholder specifically for use in connection with the preparation of
such Registration Statement, prospectus, amendment or supplement; provided, however, that the obligations of a Selling Stockholder hereunder shall be limited to an amount equal to the net proceeds to such Selling Stockholder of
Registrable Shares sold in connection with such registration. 
 (c) Each Indemnified Party shall give notice to the
Indemnifying Party promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom;
provided, that counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not be unreasonably withheld, conditioned or delayed); and,
provided, further, that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section 2.5 except to the extent that the Indemnifying Party is
adversely affected by such failure. The Indemnified Party may participate in such defense at such party’s expense; provided, however, that the Indemnifying Party shall pay such expense if the Indemnified Party reasonably concludes
that representation of such Indemnified Party by the counsel retained by the Indemnifying Party would be inappropriate due to actual or potential differing interests between the Indemnified Party and any other party represented by such counsel in
such proceeding; provided further that in no event shall the Indemnifying Party be required to pay the expenses of more than one law firm per jurisdiction as counsel for the Indemnified Party. The Indemnifying Party also shall be
responsible for the expenses of such defense if the Indemnifying Party does not elect to assume such defense. No Indemnifying Party, in the defense of any such claim or litigation shall, except with the consent of each Indemnified Party, consent to
entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect of such claim or litigation, and
no Indemnified Party shall consent to entry of any judgment or settle such claim or litigation without the prior written consent of the Indemnifying Party, which consent shall not be unreasonably withheld, conditioned or delayed. 

(d) In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in this
Section 2.5 is due in accordance with its terms but for any reason is held to be unavailable to an Indemnified Party in respect to any losses, claims, damages and liabilities referred to herein, then the Indemnifying Party shall, in lieu of
indemnifying such Indemnified Party, contribute to the amount paid or payable by such Indemnified Party as a result of such losses, claims, damages or liabilities to which such party may be subject in such proportion as is appropriate to reflect the
relative fault of the Company on the one hand and each Selling Stockholder on the other in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative fault of the Company and each Selling Stockholder shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of material fact related to information supplied by the Company or
a Selling Stockholder and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the Selling Stockholders agree that it would not be just and equitable if
contribution pursuant to this Section 2.5(d) were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to above. Notwithstanding the provisions of this
Section 2.5(d), (i) in no case shall any one Selling Stockholder be liable or responsible for any amount in excess of the net proceeds received by such Selling Stockholder from the offering of Registrable Shares and (ii) the Company
shall be liable and responsible for any amount in excess of such proceeds; provided, however, that no person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to

  
 - 10 -

 
contribution from any person who was not guilty of such fraudulent misrepresentation. Any party entitled to contribution will, promptly after receipt of notice of commencement of any action, suit
or proceeding against such party in respect of which a claim for contribution may be made against another party or parties under this Section 2.5(d), notify such party or parties from whom contribution may be sought, but the omission so to
notify such party or parties from whom contribution may be sought shall not relieve such party from any other obligation it or they may have thereunder or otherwise under this Section 2.5(d). No party shall be liable for contribution with
respect to any action, suit, proceeding or claim settled without its prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed. 
 (e) The rights and obligations of the Company and the Selling Stockholders under this Section 2.5 shall survive the termination of this Agreement. 

2.6 Other Matters with Respect to Underwritten Offerings. In the event that Registrable Shares are sold pursuant to a Registration
Statement in an underwritten offering pursuant to Section 2.1, the Company agrees to (a) enter into an underwriting agreement containing customary representations and warranties with respect to the business and operations of the Company
and customary covenants and agreements to be performed by the Company, including without limitation customary provisions with respect to indemnification by the Company of the underwriters of such offering; (b) use its best efforts to cause its
legal counsel to render customary opinions to the underwriters with respect to the Registration Statement; and (c) use its best efforts to cause its independent public accounting firm to issue customary “cold comfort letters” to the
underwriters with respect to the Registration Statement. 
 2.7 Information by Holder. Each holder of Registrable Shares
included in any registration shall furnish to the Company such information regarding such holder and the distribution proposed by such holder as the Company may reasonably request in writing and as shall be required in connection with any
registration, qualification or compliance referred to in this Agreement. 
 2.8 “Lock-Up” Agreement;
Confidentiality of Notices. Each Purchaser agrees, if requested by the Company and the managing underwriter of the Initial Public Offering, (i) not to (a) offer, pledge, announce the intention to sell, sell, contract to sell, sell any
option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly (other than as a result of a change of control of a holder of
Registrable Shares where such holder survives the change of control), any Registrable Shares or other securities of the Company (excluding securities acquired in the Initial Public Offering or in the public market after such offering) or
(b) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of any Registrable Shares or other securities of the Company (excluding securities acquired in the Initial Public
Offering or in the public market after such offering), whether any transaction described in clause (a) or (b) is to be settled by delivery of securities, in cash or otherwise, during the period beginning on the date of the filing of such
registration statement with the Securities and Exchange Commission and ending 180 days after the date of the final prospectus relating to the Initial Public Offering (plus up to an additional 34 days to the extent requested by the managing
underwriters for such offering in order to address NASD Rule 2711(f) of the Financial Industry Regulatory Authority, Inc. or NYSE Rule 472(f)(4) or any similar successor provision) and (ii) to execute any agreement reflecting clause
(i) above as may be requested by the Company or the managing underwriters at the time of such offering; provided, that all stockholders of the Company then holding at least 1% of the outstanding Common Stock (on an as-converted basis)
and all officers and directors of the Company enter into similar agreements. 
 The Company may impose stop-transfer
instructions with respect to the Registrable Shares or other securities subject to the foregoing restriction until the end of such “lock-up” period. 

  
 - 11 -

 As a condition to the obligation of the Purchasers under this Section 2.8, the Company
agrees to use reasonable efforts to ensure that the “lock-up” obligation of the Purchasers under this Section 2.8, and any agreement entered into by the Purchasers as a result of their obligations under this Section 2.8, shall
allow for periodic early releases of portions of the securities subject to such “lock-up” obligations, which may be conditioned upon the trading price of the Company’s Common Stock. The Company also agrees to use its best efforts to
ensure that the “lock-up” obligation of the Purchasers under this Section 2.8, and any agreement entered into by the Purchasers as a result of their obligation under this Section 2.8, shall provide that all Purchasers will
participate on a pro-rata basis in any early release of any stockholder. 
 Any Purchaser receiving any written notice from the
Company regarding the Company’s plans to file a Registration Statement shall treat such notice confidentially and shall not disclose such information to any person other than as necessary to exercise its rights under this Agreement. 

2.9 Limitations on Subsequent Registration Rights. The Company shall not, prior to the Initial Public Offering, without the prior
written consent of Purchasers holding at least a majority of the Registrable Shares then held by all Purchasers, enter into any agreement (other than this Agreement) with any holder or prospective holder of any securities of the Company which grants
such holder or prospective holder rights to include securities of the Company in any Registration Statement, unless (a) such rights to include securities in a registration initiated by the Company or by Purchasers are not more favorable than
the rights granted to Other Holders under Sections 2.1 and 2.2, and (b) no rights are granted to initiate a registration, other than registration pursuant to a registration statement on Form S-3 (or its successor) in which Purchasers are
entitled to include Registrable Shares on a pro rata basis with such holders based on the number of shares of Common Stock (on an as-converted basis) owned by Purchasers and such holders. 

2.10 Reports Under Exchange Act. After the earliest of (i) the closing of the sale of securities of the Company pursuant to a
Registration Statement, (ii) the registration by the Company of a class of securities under Section 12 of the Exchange Act, or (iii) the issuance by the Company of an offering circular pursuant to Regulation A under the Securities Act
and with a view to making available to the holders of Registrable Shares the benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit such holders to sell securities of the Company to the public without
registration or pursuant to a registration on Form S-3, the Company agrees to: 
 (a) make and keep current public information
about the Company available, as those terms are understood and defined in Rule 144; 
 (b) use its best efforts to file with
the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements); and 

(c) furnish to any holder of Registrable Shares upon request (i) a written statement by the Company as to its compliance with the
reporting requirements of Rule 144 and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), (ii) a copy of the most recent annual or quarterly report of the Company, and
(iii) such other reports and documents of the Company as such holder may reasonably request to avail itself of any similar rule or regulation of the Commission allowing it to sell any such securities without registration (at any time after the
Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

  
 - 12 -

 2.11 Termination. All of the Company’s obligations to register Registrable
Shares under Sections 2.1 and 2.2 shall terminate upon the earliest of (a) five years after the closing of the Initial Public Offering, (b) the date on which no Purchaser holds any Registrable Shares or (c) a Company Sale. 

3. Right of First Refusal. 
 3.1 Rights of Purchasers to Acquire Offered Securities. 
 (a) The Company
shall not issue, sell or exchange, agree to issue, sell or exchange, or reserve or set aside for issuance, sale or exchange, any Offered Securities, unless in each such case the Company shall have first complied with this Section 3.1. The
Company shall deliver to each Purchaser an Offer, which shall (i) identify and describe the Offered Securities, (ii) describe the price and other terms upon which they are to be issued, sold or exchanged, and the number or amount of the
Offered Securities to be issued, sold or exchanged, (iii) identify the persons or entities (if known) to which or with which the Offered Securities are to be offered, issued, sold or exchanged, and (iv) offer to issue and sell to or
exchange with such Purchaser that is a Qualified Purchaser (A) such Qualified Purchaser’s Basic Amount and (B) such Qualified Purchaser’s Undersubscription Amount. Notwithstanding the other provisions of this Section 3.1,
after delivery of the Offer, the Company may issue, sell or exchange, agree to issue, sell or exchange, or reserve or set aside for issuance, sale or exchange, Offered Securities to the offerees or purchasers described in the Offer and upon the
terms and conditions (including, without limitation, unit prices and interest rates) which are not more favorable, in the aggregate, to the acquiring person or persons or less favorable to the Company than those set forth in the Offer without
complying with the terms of this Section 3.1, provided that the Company permits each Qualified Purchaser to purchase the number of Offered Securities that such Qualified Purchaser is entitled to purchase pursuant to this Section 3.1
(calculated in the same manner as if such Qualified Purchasers purchased such Offered Securities on the same date as the offerees or purchasers described in the Offer) on substantially the same terms as the Company sold the Offered Securities in the
initial transaction, within 10 days after the Company receives a Notice of Acceptance from such Qualified Purchaser. 
 (b) To
accept an Offer, in whole or in part, a Qualified Purchaser must deliver to the Company, on or prior to the date 30 days after the date of delivery of the Offer, a Notice of Acceptance providing a representation letter certifying that such Qualified
Purchaser is an accredited investor within the meaning of Rule 501 under the Securities Act and indicating the portion of the Qualified Purchaser’s Basic Amount that such Qualified Purchaser elects to purchase and, if such Qualified Purchaser
shall elect to purchase all of its Basic Amount, the Undersubscription Amount (if any) that such Qualified Purchaser elects to purchase. If the Basic Amounts subscribed for by all Qualified Purchasers are less than the total of all of the Basic
Amounts available for purchase, then each Qualified Purchaser who has set forth an Undersubscription Amount in its Notice of Acceptance shall be entitled to purchase, in addition to the Basic Amounts subscribed for, the Undersubscription Amount it
has subscribed for; provided, however, that if the Undersubscription Amounts subscribed for exceed the Available Undersubscription Amount, each Qualified Purchaser who has subscribed for any Undersubscription Amount shall be entitled
to purchase only that portion of the Available Undersubscription Amount as the Undersubscription Amount subscribed for by such Qualified Purchaser bears to the total Undersubscription Amounts subscribed for by all Purchasers, subject to rounding by
the Board of Directors to the extent it deems reasonably necessary. 
 (c) The Company shall have 90 days from the expiration
of the period set forth in Section 3.1(b) to issue, sell or exchange all or any part of the Refused Securities other than previously sold under the last sentence of Section 3.1(a), but only to the offerees or purchasers described in the
Offer (if so described therein) and only upon terms and conditions (including, without limitation, unit prices and interest rates) which are not more favorable, in the aggregate, to the acquiring person or persons or less favorable to the Company
than those set forth in the Offer. 

  
 - 13 -

 (d) In the event the Company shall propose to sell less than all the Refused Securities,
then each Qualified Purchaser may, at its sole option and in its sole discretion, reduce the number or amount of the Offered Securities specified in its Notice of Acceptance to an amount that shall be not less than the number or amount of the
Offered Securities that the Qualified Purchaser elected to purchase pursuant to Section 3.1(b) multiplied by a fraction, (i) the numerator of which shall be the number or amount of Offered Securities the Company actually proposes to issue,
sell or exchange (including Offered Securities to be issued or sold to Qualified Purchasers pursuant to Section 3.1(b) prior to such reduction) and (ii) the denominator of which shall be the original amount of the Offered Securities. In
the event that any Qualified Purchaser so elects to reduce the number or amount of Offered Securities specified in its Notice of Acceptance, the Company may not issue, sell or exchange more than the reduced number or amount of the Offered Securities
unless and until such securities have again been offered to the Qualified Purchasers in accordance with Section 3.1(a). 

(e) Upon (i) the closing of the issuance, sale or exchange of all or less than all of the Refused Securities or (ii) such
other date agreed to by the Company and Qualified Purchasers who have subscribed for a majority of the Offered Securities subscribed for by the Qualified Purchasers, such Qualified Purchaser or Purchasers shall acquire from the Company and the
Company shall issue to such Qualified Purchaser or Purchasers, the number or amount of Offered Securities specified in the Notices of Acceptance, as reduced pursuant to Section 3.1(d) if any of the Qualified Purchasers has so elected, upon the
terms and conditions specified in the Offer. 
 (f) The purchase by the Qualified Purchasers of any Offered Securities is
subject in all cases to the preparation, execution and delivery by the Company and the Qualified Purchasers of a purchase agreement relating to such Offered Securities reasonably satisfactory in form and substance to the Qualified Purchasers and
their respective counsel. 
 (g) Any Offered Securities not acquired by the Qualified Purchasers or other persons in accordance
with Section 3.1(c) may not be issued, sold or exchanged until they are again offered to the Qualified Purchasers under the procedures specified in this Agreement. 
 (h) The rights of the Qualified Purchasers under this Section 3.1 shall not apply to: 
 (i) the issuance of any shares of Common Stock as a stock dividend to holders of Common Stock or upon any subdivision or combination of shares of Common Stock; 

(ii) the issuance of any shares of Common Stock upon conversion of shares of outstanding convertible preferred stock; 

(iii) the issuance of up to an aggregate of 10,669,018 shares (including shares issued prior to the date hereof) of Common Stock (or
such greater number as is approved by the Board of Directors of the Company, including at least a majority of the Series A Directors and all of the Independent Directors) or options with respect thereto (subject in either case to appropriate
adjustment for stock splits, stock dividends, recapitalizations and similar events occurring after the date of this Agreement), issued or issuable to employees, directors or officers of, or consultants to, the Company or any Company Subsidiary
pursuant to any plan, agreement or arrangement approved by the Board of Directors of the Company, including at least a majority of the Series A Directors and all of the Independent Directors (it being understood that any shares subject to options
that expire or 

  
 - 14 -

 
terminate unexercised or any restricted stock repurchased by the Company shall not be counted towards the maximum number set forth in this clause (iii) unless and until regranted or reissued
pursuant to any such plan, agreement or arrangement); 
 (iv) the issuance of securities solely in consideration for the
acquisition (whether by merger or otherwise) by the Company or any Company Subsidiary of all or substantially all of the stock or assets of any other entity (which issuance is approved by the Board of Directors, including at least a majority of the
Series A Directors and all of the Independent Directors); 
 (v) the issuance of shares of Common Stock by the Company in a
firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act; or 

(vi) the issuance of shares of Common Stock, or the grant of options or warrants therefor, in connection with any present or future
borrowing, line of credit, leasing or similar financing arrangement approved by the Board of Directors of the Company, including at least a majority of the Series A Directors and all of the Independent Directors; 

(vii) the issuance of shares of Common Stock, or the grant of options or warrants therefor, pursuant to a joint venture agreement,
provided, that such issuances are approved by the Board of Directors of the Corporation, including at least a majority of the Series A Directors and all of the Independent Directors; or 

(viii) the issuance of shares of Common Stock, or the grant of options or warrants therefor, in connection with sponsored research,
collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board of Directors of the Corporation, including at least a majority of the Series A Directors and all of the
Independent Directors. 
 3.2 Termination. This Section 3 shall terminate upon the earlier of the closing of a
Company Sale or the closing of the Initial Public Offering. 
 4. Covenants. 

4.1 Negative Covenants. So long as at least 1,000,000 Shares (subject to appropriate adjustment for stock splits, stock dividends,
recapitalizations and similar events occurring after the date of this Agreement) are outstanding, the Company shall not, without the consent of the Board of Directors, including at least a majority of the Series A Directors and all of the
Independent Directors: 
 (a) increase the size of the Board of Directors above nine (9) members; 

(b) hire or fire any senior executives or change the compensation of (including approving the payment of bonuses to) senior executives
not contemplated in the Budget (as defined below) or such executives’ employment agreements; 
 (c) make any investment
other than investments in prime commercial paper, money market funds, certificates of deposit in any United States bank having a net worth in excess of $100,000,000 or obligations issued or guaranteed by the United States of America, in each case
having a maturity not in excess of one year; 

  
 - 15 -

 (d) enter into any lines of business that are not primarily related to the business of the
Company as conducted on the date hereof, exit the business of the Company as conducted on the date hereof, or change the principal business of the Company; 
 (e) grant an exclusive license to any of the Company’s material intellectual property rights; 
 (f) acquire all or substantially all of the properties, assets or stock of any other company or entity; 
 (g) incur indebtedness in excess of $100,000 in the aggregate that is not covered by the Budget, other than trade credit incurred in the ordinary course of business; 

(h) make any loan or advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other
entity unless it is wholly owned by the Company; 
 (i) make any loan or advance to any person, including, any employee or
director, except advances and similar expenditures in the ordinary course of business or under the terms of a employee stock or option plan approved by the Board of Directors; 

(j) guarantee, any indebtedness except for trade accounts of the Company or any subsidiary arising in the ordinary course of business;
or 
 (k) enter into or be a party to any transaction with any director, officer or employee of the Company or any
“associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such person. 
 4.2
Observation. 
 (a) The Company will permit one designee of the Founders, who shall be a Founder then serving on the
Company’s scientific advisory board who is not an employee of or a member of the Board of Directors of the Company, to attend all meetings of the Board of Directors of the Company, and shall provide such Founder with such notice and other
information with respect to such meetings as are delivered to the directors of the Company. Notwithstanding the foregoing, the Company may prevent such Founder from attending a Board of Directors meeting (or portion thereof) or receiving certain
information with respect thereto if the Company’s Board of Directors reasonably believes that the delivery of such information or the attendance at such meeting (i) would result in the loss of trade secret protection or otherwise
compromise confidential information or (ii) would adversely affect attorney-client privilege. 
 (b) As long as the
Fidelity Purchasers do not have a representative serving on the Board of Directors of the Company, the Company will permit one designee of the Fidelity Purchasers (the “Fidelity Designee”), who shall be reasonably acceptable to the
Company, to attend meetings of the Board of Directors of the Company, and shall provide the Fidelity Designee with such notice and other information with respect to such meetings as are delivered to the directors of the Company. Notwithstanding the
foregoing, the Board of Directors of the Company may prevent the Fidelity Designee from attending a Board of Directors meeting (or portion thereof) or receiving certain information with respect thereto if the Company’s Board of Directors
reasonably believes that the delivery of such information or the attendance at such meeting (i) would result in the loss of trade secret protection or otherwise compromise confidential information or (ii) would adversely affect
attorney-client privilege. 

  
 - 16 -

 4.3 Financial Statements and Budget. The Company shall deliver to each Purchaser:

 (a) within 120 days after the end of each fiscal year of the Company, an audited balance sheet of the Company as at the
end of such year and audited statements of income and of cash flows of the Company for such year, certified by certified public accountants of established regional or national reputation selected by the Company, and prepared in accordance with
generally accepted accounting principles consistently applied; 
 (b) within 30 days after the end of each of the first three
fiscal quarters of the Company and within 60 days after the end of the fourth fiscal quarter of the Company, an unaudited balance sheet of the Company as at the end of such quarter, and unaudited statements of income and of cash flows of the Company
for such fiscal quarter and for the current fiscal year to the end of such fiscal quarter; 
 (c) within 30 days after the end
of each month (other than the last month of any fiscal quarter), an unaudited balance sheet of the Company as at the end of such month and unaudited statements of income and of cash flows of the Company for such month and for the current fiscal year
to the end of such month, setting forth in comparative form the Company’s projected financial statements for the corresponding periods for the current fiscal year; 
 (d) at least 30 days prior to the commencement of each new fiscal year, a budget (the “Budget”) approved by the Board of Directors of the Company for such fiscal year; provided
that any budget provided to Celgene may be revised to exclude any information that the Company reasonably believes would (i) identify parties to existing business transactions or business transactions under negotiation (provided that the budget
shall retain information sufficient for Celgene to understand the impact of the budget on the Company’s financial condition) or (ii) reveal sensitive or strategic information related to a potential or existing conflict of interest between
Celgene and the Company with respect to the Collaboration Agreement; and 
 (e) promptly following the end of each fiscal
quarter of the Company, an updated capitalization table of the Company certified by the Treasurer of the Company. 
 Upon the
request of any Purchaser, the Company will use commercially reasonable efforts to advise such Purchaser if the Company believes there may be material non-public information about any other company that has any class of its equity securities traded
publicly in any part of the world in any of the materials provided to such Purchaser under this Section 4.3. 
 4.4
Agreements with Employees; Options. 
 (a) Subject to the policies of any academic or research institutions with whom
the Company’s consultants or advisors may be affiliated, the Company (A) shall require all persons now or hereafter employed by the Company to enter into non-competition, non-solicitation confidentiality and assignment agreements
substantially in the form of Exhibit G to the Purchase Agreement and (B) shall require all consultants utilized by the Company to enter into such invention and non-disclosure agreements and/or non-competition and non-solicitation agreements as
may be required by the Board of Directors of the Company. 
 (b) Unless otherwise approved by the Board of Directors, including
at least a majority of the Series A Directors and all of the Independent Directors, all options or restricted stock granted or issued by the Company after the date hereof to employees or consultants shall become exercisable at the rate of 25% on the
first anniversary of the date of grant or issue and 2.0833% per month thereafter over the subsequent three (3) years, so long as the holder continues to be an employee or consultant of the Company. 

  
 - 17 -

 4.5 Board of Directors. 

(a) The Company shall promptly reimburse in full each director of the Company who is not an employee of the Company for all of his or
her reasonable out-of-pocket expenses incurred in attending each meeting of the Board of Directors of the Company or any committee thereof. 
 (b) The Board of Directors shall meet at least eight (8) times per year (whether in person or by teleconference), unless otherwise agreed by a majority of the members of the Board of Directors.

 (c) The Company shall obtain as promptly as practicable following the date of this Agreement and shall maintain, until
otherwise approved by a majority of the Board of Directors who are not employees of the Company, a director and officer liability insurance policy on terms approved by a majority of the members of the Board of Directors who are not employees of the
Company. 
 (d) The Company hereby acknowledges that one or more of the Series A Directors may have certain rights to
indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees (i) that it is the indemnitor
of first resort (i.e., its obligations to any such Series A Director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Series A Director are
secondary), (ii) that it shall be required to advance the full amount of expenses incurred by such Series A Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on
behalf of any such Series A Director to the extent legally permitted and as required by the Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Series A Director), without regard to any rights such
Series A Director may have against the Fund Indemnitors, and, (iii) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other
recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of any such Series A Director with respect to any claim for which such Series A Director has sought indemnification
from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Series A Director against the Company.

 (e) In the event that the Company or any of its successors or assigns (i) consolidates with or merges into any other
entity and shall not be the continuing or surviving corporation in such consolidation or merger or (ii) transfers or conveys all or substantially all of its properties and assets to any entity, then, and in each such case, to the extent
necessary, proper provision shall be made so that the successors and assigns of the Company to assume the obligations of the Company with respect to indemnification of members of the Board of Directors as contained in the Company’s Third
Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time. 
 (f) Each committee of the
Board of Directors shall contain at least one Series A Director and at least one Independent Director. 
 4.6 Termination of
Covenants. All covenants of the Company contained in this Section 4 (except the covenants set forth in Section 4.5(d) and (e)) shall terminate upon the earlier of the closing of a Company Sale or the closing of the Initial Public
Offering. 

  
 - 18 -

 5. Confidentiality; Acknowledgement of Investor Activity. 

(a) Each Purchaser agrees that he, she or it will keep confidential and will not disclose, divulge or use for any purpose, other than to
monitor its investment in the Company, any Confidential Information, unless such Confidential Information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 5.1 by such Purchaser),
(b) is or has been independently developed or conceived by the Purchaser without use of the Company’s Confidential Information or (c) is or has been made known or disclosed to the Purchaser by a third party without a breach of any
obligation of confidentiality such third party may have to the Company; provided, however, that a Purchaser may disclose Confidential Information (i) to its attorneys, accountants, consultants, and other professionals to the
extent necessary to obtain their services in connection with monitoring its investment in the Company, (ii) to any prospective purchaser of any Shares from such Purchaser as long as such prospective purchaser agrees to be bound by the
provisions of this Section 5.1, (iii) to any Affiliated Party of such Purchaser, provided that such party is obligated not to disclose, divulge or use any Confidential Information to the same extent as the Purchasers, or (iv) as may
otherwise be required by law, regulation or legal process, provided that the Purchaser takes reasonable steps to minimize the extent of any such required disclosure. Notwithstanding the foregoing, such information shall not be deemed confidential
for the purpose of enforcing this Agreement. 
 (b) The Company acknowledges that certain of the Investors are registered
Investment Companies under the Investment Company Act of 1940, as amended, other investment funds or in the business of venture capital investing and therefore review the business plans and related proprietary information of many enterprises,
including enterprises that may have products or services that compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular
enterprise whether or not such enterprise has products or services which compete with those of the Company; provided that the Investors remain in compliance with the confidentiality obligations set forth above in Section 5.1. 

6. Transfers of Rights; Calculation of Share Numbers. 
 6.1 Transfer of Rights. This Agreement, and the rights and obligations of each Purchaser hereunder, may be assigned by such Purchaser to (a) any person or entity to which at least 600,000
Shares (subject to appropriate adjustment for stock splits, stock dividends, recapitalizations and similar events occurring after the date of this Agreement) or all of the Shares owned by such Purchaser (if fewer than 600,000) are transferred by
such Purchaser, or (b) to any Affiliated Party of such Purchaser, and, in each case, such transferee shall be deemed a “Purchaser” for purposes of this Agreement; provided that such assignment of rights shall be contingent upon the
transferee providing a written instrument to the Company notifying the Company of such transfer and assignment and agreeing in writing to be bound by the terms of this Agreement. Notwithstanding the foregoing, any person or entity to which any
Shares or Registrable Shares are transferred by a Purchaser, whether voluntarily or by operation of law, shall be bound by the obligations under Section 2.8 to the same extent as if such transferee were a Purchaser hereunder and no Purchaser
shall transfer any Shares or Registrable Shares unless the transferee provides a written instrument to the Company notifying the Company of such transfer and agreeing in writing to be bound by the terms of Section 2.8. 

6.2 Calculation of Share Numbers. In determining the number of Shares owned by a Purchaser for purposes of exercising rights under
this Agreement, (a) Shares owned by a Purchaser shall be deemed to include Shares which have been converted into Common Stock so long as such Common Stock is owned by such Purchaser and (b) all Shares held by affiliated entities or persons
shall be aggregated together (provided that no shares shall be attributed to more than one entity or person within any such group of affiliated entities or persons). 

  
 - 19 -

 7. General. 
 7.1 Massachusetts Business Trust. A copy of the Agreement and Declaration of Trust of each of Fidelity Purchaser or any affiliate thereof is on file with the Secretary of State of the Commonwealth
of Massachusetts and notice is hereby given that this Agreement is executed on behalf of the trustees of such Fidelity Purchaser or any affiliate thereof as trustees and not individually and that the obligations of this Agreement are not binding on
any of the trustees, officers or stockholders of such Fidelity Purchaser or any affiliate thereof individually but are binding only upon such Fidelity Purchaser or any affiliate thereof and its assets and property. 

7.2 Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or
enforceability of any other provision of this Agreement. 
 7.3 Specific Performance. In addition to any and all other
remedies that may be available at law in the event of any breach of this Agreement, each Purchaser shall be entitled to specific performance of the agreements and obligations of the Company hereunder and to such other injunctive or other equitable
relief as may be granted by a court of competent jurisdiction. 
 7.4 Governing Law. This Agreement shall be governed by
and construed in accordance with the General Corporation Law of the State of Delaware, as to matters within the scope thereof, and the internal laws of the Commonwealth of Massachusetts (without reference to the conflicts of law provisions thereof),
as to all other matters. 
 7.5 Notices. All notices, requests, consents and other communications under this Agreement
shall be in writing and shall be deemed delivered (i) three business days after being sent by registered or certified mail, return receipt requested, postage prepaid, (ii) one business day after being sent via a reputable nationwide
overnight courier service guaranteeing next business day delivery or (iii) immediately upon confirmation of receipt if delivered by e-mail, in each case to the intended recipient as set forth below: 

If to the Company, at 38 Sidney Street, 2nd Floor, Cambridge, Massachusetts 02139, Attention: President, or at such other address as may
have been furnished in writing by the Company to the other parties hereto, with a copy to Wilmer Cutler Pickering Hale and Dorr LLP, 399 Park Avenue, New York, NY 10022, Attention: Steven D. Singer, Esq.; 

If to a Purchaser, at its address set forth on Exhibit A, or at such other address as may have been furnished in writing by
such Purchaser to the other parties hereto; or 
 If to a Founder, at the address set forth below such Founder’s signature
to this Agreement, or at such other address as may have been furnished in writing by such Founder to the other parties hereto. 

For purposes of clarity, any notice to Salthill Partners, L.P., Salthill Investors (Bermuda) L.P. and Hawkes Bay Master Investors
(Cayman) LP (each a “Wellington Purchaser”) shall be exclusively delivered to the Wellington Management Company, LLP at the address set forth on Exhibit A hereto unless otherwise directed by such Wellington Purchaser.

 Any party may give any notice, request, consent or other communication under this Agreement using any other means (including,
without limitation, personal delivery, messenger service, telecopy, first class mail or electronic mail), but no such notice, request, consent or other communication shall be deemed to have been duly given unless and until it is actually received by
the party for whom it is intended. Any party may change the address to which notices, requests, consents or other communications hereunder are to be delivered by giving the other parties notice in the manner set forth in this Section 7.4.

  
 - 20 -

 7.6 Amendment and Restatement of Prior Agreement; Complete Agreement. The Company and
the Purchasers (as defined in the Prior Agreement) holding Shares representing a majority of the voting power of all Shares held by Purchasers (as defined in the Prior Agreement) agree that, as of the date of this Agreement, (i) the Prior
Agreement is hereby amended and restated in its entirety by this Agreement, (ii) the provisions of the Prior Agreement shall no longer be of any force or effect, and (iii) this Agreement constitutes the entire agreement and understanding
of the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings relating to such subject matter. 
 7.7 Amendments and Waivers. This Agreement may be amended or terminated and the observance of any term of this Agreement may be waived with respect to all parties to this Agreement (either
generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and Purchasers holding Shares representing a majority of the voting power of all Shares then held by Purchasers; provided that
any amendment, termination or waiver to the terms of Section 2 (or a defined term used therein) that occurs after the closing of the Initial Public Offering shall instead require the written consent of the Company and Purchasers holding
Registrable Shares representing a majority of the voting power of all Registrable Shares then held by all Purchasers. Notwithstanding the foregoing, (a) this Agreement may not be amended or terminated and the observance of any term hereunder
may not be waived with respect to any Purchaser without the written consent of such Purchaser unless such amendment, termination or waiver applies to all Purchasers in the same fashion (it being agreed that a waiver of the provisions of
Section 3 with respect to a particular transaction shall be deemed to apply to all Purchasers in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Purchasers may nonetheless, by agreement with the
Company, purchase securities in such transaction), (b) this Agreement may not be amended or terminated and the observance of any term hereunder may not be waived in a manner that is adverse to the holders of Series C-1 Convertible Preferred
Stock and not similarly adverse to the other holders of Preferred Stock without the written consent of the holders of a majority of the outstanding shares of Series C-1 Convertible Preferred Stock (the “Requisite Series C-1 Vote”),
(c) Section 4.2(a) may not be amended or waived without the written consent of holders of at least a majority of the Founders then employed by or engaged as a consultant or advisor to the Company, (d) Sections 4.2(b) and 4.3 may not
be amended and the observance thereof may not be waived without the written consent of the Requisite Series C-1 Vote, and (e) any requirement to obtain to the approval of all of the Independent Directors may not be amended or terminated and the
observance thereof may not be waived without the written consent of the Requisite Series C-1 Vote. The Company shall give prompt written notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in
writing to such amendment, termination or waiver. Any amendment, termination or waiver effected in accordance with this Section 7.7 shall be binding on all parties hereto, even if they do not execute such consent. No waivers of or exceptions to
any term, condition or provision of this Agreement, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision. 

7.8 Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine,
feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa. 
 7.9
Counterparts; Facsimile Signatures. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same document. This Agreement may be
executed by facsimile signatures. 

  
 - 21 -

 7.10 Section Headings and References. The section headings are for the convenience of
the parties and in no way alter, modify, amend, limit or restrict the contractual obligations of the parties. Any reference in this agreement to a particular section or subsection shall refer to a section or subsection of this Agreement, unless
specified otherwise. 
 [Remainder of Page Intentionally Left Blank] 

  
 - 22 -

 Executed as of the date first written above. 

 

			
	COMPANY:
	
	AGIOS PHARMACEUTICALS, INC.
		
	By:	 	 /s/ David Schenkein

	Name:	 	David Schenkein
	Title:	 	Chief Executive Officer
	
	FOUNDERS:
	
	 /s/ Lewis Cantley

	Lewis Cantley
	Address:	 	43 Larch Road
		 	Cambridge, MA 02138
	
	 /s/ Tak Mak

	Tak Mak
	Address:	 	The Campbell Family Institute for Breast Cancer Research
		 	620 University Avenue, Suite 706
		 	Toronto, Ontario
		 	Canada M5G 2C1
	
	 /s/ Craig Thompson

	Craig Thompson
	Address:	 	304 Mallwyd Road
		 	Merion, PA 19066
	
	 /s/ Michael Su

	Michael Su
	Address:	 	346 Hartman Road
		 	Newton, MA 02459

 Second Amended and Restated Investor Rights Agreement 

 
			
	PURCHASERS:
	
	ARCH VENTURE FUND VII, L.P.
		
	By:	 	ARCH Venture Partners VII, L.P.
	Its:	 	General Partner
		
	By:	 	ARCH Venture Partners VII, LLC
	Its:	 	General Partner
		
	By:	 	 /s/ Robert Nelsen

	Name:	 	  

	Title:	 	  

	
	FLAGSHIP VENTURES FUND 2007, L.P.
		
	By:	 	Flagship Ventures 2007 General Partner LLC
	Its:	 	General Partner
		
	By:	 	 /s/ Noubar Afeyan

	Name:	 	  

	Title:	 	  

	
	THIRD ROCK VENTURES, L.P.
		
	By:	 	Third Rock Ventures GP, L.P.
	Its:	 	General Partner
		
	By:	 	TRV GP, LLC
	Its:	 	General Partner
		
	By:	 	 /s/ Kevin Starr

	Name:	 	  

	Title:	 	 Manager

	
	PRINCESS MARGARET HOSPITAL FOUNDATION
		
	By:	 	 /s/ Paul Alofs

	Name:	 	 Paul Alofs

	Title:	 	 President and CEO

 Second Amended and Restated Investor Rights Agreement 

 
			
	BIOTECHNOLOGY VALUE FUND, L.P.
		
	By:	 	BVF Partners, L.P.
	Its:	 	General Partner
		
	By:	 	BVF, Inc.
	Its:	 	General Partner
		
	By:	 	 /s/ Mark Lampert

			
	Name:	 	 Mark Lampert

	Title:	 	 President

			
	
	BIOTECHNOLOGY VALUE FUND II, L.P.
		
	By:	 	BVF Partners, L.P.
	Its:	 	General Partner
		
	By:	 	BVF, Inc.
	Its:	 	General Partner
		
	By:	 	 /s/ Mark Lampert

			
	Name:	 	 Mark Lampert

	Title:	 	 President

	
	BVF INVESTMENTS, L.L.C.

 
			
		
	By:	 	BVF Partners, L.P.
	Its:	 	Manager
		
	By:	 	BVF, Inc.
	Its:	 	General Partner
		
	By:	 	 /s/ Mark Lampert

			
	Name:	 	 Mark Lampert

	Title:	 	 President

	
	INVESTMENT 10, LLC

 
			
		
	By:	 	BVF Partners, L.P.
	Its:	 	Attorney-in-fact
		
	By:	 	BVF, Inc.
	Its:	 	General Partner
		
	By:	 	 /s/ Mark Lampert

			
	Name:	 	 Mark Lampert

	Title:	 	 President

 Second Amended and Restated Investor Rights Agreement 

 
			
	CELGENE EUROPEAN INVESTMENT COMPANY LLC

 
			
		
	By:	 	 /s/ Paul D’Angio

			
	Name:	 	 Paul D’Angio

	Title:	 	 Managing Director

	
	HAWKES BAY MASTER INVESTORS (CAYMAN) LP

 
			
		
	By:	 	 /s/ Steven Hoffman

			
	Name:	 	 Steven Hoffman

	Title:	 	 Vice President and
Counsel

 
			
	By:	 	 Wellington Management Company, LLP, as

		 	 Investment Advisor for and on behalf of Hawkes

		 	 Bay Master Investors (Cayman)
LP

 
			
	
	SALTHILL INVESTORS (BERMUDA) L.P.

 
			
		
	By:	 	 /s/ Steven Hoffman

			
	Name:	 	 Steven Hoffman

	Title:	 	 Vice President and
Counsel

 
			
	By:	 	 Wellington Management Company, LLP, as

		 	 Investment Advisor for and on behalf of Salthill

		 	 Investors (Bermuda)
L.P.

 
			
	
	SALTHILL PARTNERS, L.P.

 
			
		
	By:	 	 /s/ Steven Hoffman

			
	Name:	 	 Steven Hoffman

	Title:	 	 Vice President and
Counsel

 
			
	By:	 	 Wellington Management Company, LLP, as

		 	 Investment Advisor for and on behalf of Salthill

		 	 Partners, L.P.

 Second Amended and Restated Investor Rights Agreement 

 
			
	WUXI PHARMATECH HEALTHCARE FUND I L.P.
		
	By:	 	 /s/ Edward Hu

		 	For and on behalf of
		 	WuXi PharmaTech Investments (Cayman) INC.
		 	As General Partner for and on behalf of
		 	WuXi PharmaTech Fund I General Partner L.P.

 Second Amended and Restated Investor Rights Agreement 

 
			
	FIDELITY SELECT PORTFOLIOS: PHARMACEUTICALS PORTFOLIO

 
			
		
	By:	 	 /s/ Jeffrey Christian

			
	Name:	 	 Jeffrey Christian

	Title:	 	 Deputy Treasurer

	
	FIDELITY SELECT PORTFOLIOS: BIOTECHNOLOGY PORTFOLIO

 
			
		
	By:	 	 /s/ Jeffrey Christian

			
	Name:	 	 Jeffrey Christian

	Title:	 	 Deputy Treasurer

	
	FIDELITY ADVISOR SERIES VII: FIDELITY ADVISOR BIOTECHNOLOGY FUND

 
			
		
	By:	 	 /s/ Jeffrey Christian

			
	Name:	 	 Jeffrey Christian

	Title:	 	 Deputy Treasurer

	
	FIDELITY MT. VERNON STREET TRUST: FIDELITY GROWTH COMPANY FUND

 
			
		
	By:	 	 /s/ Jeffrey Christian

			
	Name:	 	 Jeffrey Christian

	Title:	 	 Deputy Treasurer

	
	FIDELITY CONTRAFUND: FIDELITY ADVISOR NEW INSIGHTS FUND

 
			
		
	By:	 	 /s/ Jeffrey Christian

			
	Name:	 	 Jeffrey Christian

	Title:	 	 Deputy Treasurer

	
	FIDELITY SECURITIES FUND: FIDELITY SMALL CAP OPPORTUNITIES FUND

 
			
		
	By:	 	 /s/ Jeffrey Christian

			
	Name:	 	 Jeffrey Christian

	Title:	 	 Deputy Treasurer

	
	FIDELITY CAPITAL TRUST: FIDELITY SMALL CAP INDEPENDENCE FUND

 
			
		
	By:	 	 /s/ Jeffrey Christian

			
	Name:	 	 Jeffrey Christian

	Title:	 	 Deputy Treasurer

 Second Amended and Restated Investor Rights Agreement 

 Exhibit A 
 List of Purchasers 
 Name and Address 

ARCH Venture Fund VII, L.P. 
 c/o ARCH Venture
Partners 
 8725 West Higgins Road 

Suite 290 
 Chicago, IL 60631 

Flagship Ventures Fund 2007, L.P. 
 One Memorial
Drive 
 7th Floor 
 Cambridge, MA 02142

 Third Rock Ventures, L.P. 
 29
Newbury Street, Suite 401 
 Boston, MA 02116 
 ATTN: Kevin Starr 
 Princess Margaret Hospital Foundation 

8th Floor, 700 University Avenue 
 M5G 1Z5

 Toronto, Ontario, Canada 
 Attn: Paul
Alofs, President and CEO 
 Celgene European Investment Company LLC 
 86 Morris Avenue 
 Summit, NJ 07901 
 Attention: George S. Golumbeski 
 With a copy to: 

Celgene Corporation 
 86 Morris Avenue 
 Summit, NJ 07901 

Attention: Legal Department 

WuXi PharmaTech Healthcare Fund I L.P. 
 c/o
WuXi AppTec Co. Ltd. 
 288 FuTe Zhong Road 
 Wai Gao Qiao Free Trade Zone 
 Shanghai 200131 

P.R.CHINA 
 Attn: Ge Li 

  
 A-1

 Fidelity Select Portfolios: Pharmaceuticals Portfolio 

c/o Fidelity Investments 
 82 Devonshire Street,
V13H 
 Boston, MA 02109 
 Attn: Andrew
Boyd 
 With a copy (which shall not constitute notice) to: 

H. David Henken, Esq. 
 Goodwin|Procter LLP 
 Exchange Place 

Boston, MA 02109 
 Fidelity
Select Portfolios: Biotechnology Portfolio 
 c/o Fidelity Investments 
 82 Devonshire Street, V13H 
 Boston, MA 02109 

Attn: Andrew Boyd 
 With a copy
(which shall not constitute notice) to: 
 H. David Henken, Esq. 

Goodwin|Procter LLP 
 Exchange Place 
 Boston, MA 02109 

Fidelity Advisor Series VII: Fidelity Advisor 

Biotechnology Fund 
 c/o Fidelity Investments

 82 Devonshire Street, V13H 
 Boston,
MA 02109 
 Attn: Andrew Boyd 
 With a copy (which shall not constitute notice) to: 
 H. David Henken, Esq.

 Goodwin|Procter LLP 
 Exchange Place 
 Boston, MA 02109 

Fidelity Mt. Vernon Street Trust: Fidelity Growth 
 Company Fund 
 c/o Fidelity Investments 
 82 Devonshire Street, V13H 
 Boston, MA 02109 

Attn: Andrew Boyd 
 With a copy
(which shall not constitute notice) to: 
 H. David Henken, Esq. 

Goodwin|Procter LLP 
 Exchange Place 
 Boston, MA 02109 

  
 A-2

 Fidelity Contrafund: Fidelity Advisor New Insights Fund 

c/o Fidelity Investments 
 82 Devonshire Street,
V13H 
 Boston, MA 02109 
 Attn: Andrew
Boyd 
 With a copy (which shall not constitute notice) to: 

H. David Henken, Esq. 
 Goodwin|Procter LLP 
 Exchange Place 

Boston, MA 02109 
 Fidelity
Securities Fund: Fidelity Small Cap Opportunities Fund 
 Ball & Co 
 c/o Fidelity Investments 
 82 Devonshire Street, V13H 

Boston, MA 02109 
 Attn: Andrew Boyd 

With a copy (which shall not constitute notice) to: 
 H. David Henken, Esq. 
 Goodwin|Procter LLP 

Exchange Place 

Boston, MA 02109 
 Fidelity
Capital Trust: Fidelity Small Cap 
 Independence Fund 
 c/o Fidelity Investments 
 82 Devonshire Street, V13H 

Boston, MA 02109 
 Attn: Andrew Boyd 

With a copy (which shall not constitute notice) to: 
 H. David Henken, Esq. 
 Goodwin|Procter LLP 

Exchange Place 

Boston, MA 02109 
 Biotechnology
Value Fund II, L.P. 
 Attn: Scott Perlen, VP – Finance 
 Grosvenor Capital Management, L.P. 
 900 N. Michigan Avenue, Suite 1100 

Chicago, IL 60611 
 Biotechnology Value Fund,
L.P. 
 Attn: Scott Perlen, VP – Finance 
 Grosvenor Capital Management, L.P. 
 900 N. Michigan Avenue, Suite 1100 

Chicago, IL 60611 

  
 A-3

 BVF Investments, L.L.C. 
 Attn: Scott Perlen, VP – Finance 
 Grosvenor Capital Management, L.P. 

900 N. Michigan Avenue, Suite 1100 
 Chicago, IL
60611 
 Investment 10, LLC 
 Attn:
Scott Perlen, VP – Finance 
 Grosvenor Capital Management, L.P. 
 900 N. Michigan Avenue, Suite 1100 
 Chicago, IL 60611 

Salthill Partners, L.P. 
 c/o Wellington
Management Company, LLP 
 280 Congress Street 
 Boston, MA 02210 
 Attention: Steven Hoffman, VP and Counsel 

email: seclaw@wellington.com 
 Salthill
Investors (Bermuda) L.P. 
 c/o Wellington Management Company, LLP 
 280 Congress Street 
 Boston, MA 02210 
 Attention: Steven Hoffman, VP and Counsel 
 email: seclaw@wellington.com 

Hawkes Bay Master Investors (Cayman) LP 
 c/o
Wellington Management Company, LLP 
 280 Congress Street 
 Boston, MA 02210 
 Attention: Steven Hoffman, VP and Counsel 

email: seclaw@wellington.com 

  
 A-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}]]